Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Receivables (2019 - 2025)

C4 Therapeutics' Receivables history spans 7 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Receivables fell 22.6% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, down 22.6%, while the annual FY2025 figure was $2.4 million, 22.6% down from the prior year.
  • Receivables reached $2.4 million in Q4 2025 per CCCC's latest filing, down from $6.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $13.6 million in Q1 2024 to a low of $500000.0 in Q3 2023.
  • Average Receivables over 5 years is $4.4 million, with a median of $2.8 million recorded in 2024.
  • Peak YoY movement for Receivables: plummeted 74.23% in 2022, then skyrocketed 2475.57% in 2024.
  • A 5-year view of Receivables shows it stood at $5.7 million in 2021, then tumbled by 74.23% to $1.5 million in 2022, then skyrocketed by 701.02% to $11.8 million in 2023, then plummeted by 73.71% to $3.1 million in 2024, then decreased by 22.6% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Receivables are $2.4 million (Q4 2025), $6.5 million (Q3 2025), and $2.2 million (Q2 2025).